Seer (SEER) and Its Peers Head-To-Head Analysis

Seer (NASDAQ:SEERGet Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Seer to related companies based on the strength of its analyst recommendations, dividends, profitability, valuation, institutional ownership, risk and earnings.

Volatility and Risk

Seer has a beta of 3.13, suggesting that its stock price is 213% more volatile than the S&P 500. Comparatively, Seer’s competitors have a beta of 1.21, suggesting that their average stock price is 21% more volatile than the S&P 500.

Earnings and Valuation

This table compares Seer and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Seer $6.62 million -$71.17 million -5.83
Seer Competitors $1.16 billion $344.59 million -22.44

Seer’s competitors have higher revenue and earnings than Seer. Seer is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Seer and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Seer -794.43% -15.44% -14.71%
Seer Competitors -250.85% 6.38% -11.11%

Institutional and Insider Ownership

86.9% of Seer shares are owned by institutional investors. Comparatively, 62.0% of shares of all “Analytical instruments” companies are owned by institutional investors. 28.9% of Seer shares are owned by insiders. Comparatively, 13.4% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Seer and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seer 0 1 1 0 2.50
Seer Competitors 147 960 1633 50 2.57

Seer currently has a consensus target price of $21.00, indicating a potential upside of 183.78%. As a group, “Analytical instruments” companies have a potential upside of 48.25%. Given Seer’s higher possible upside, analysts clearly believe Seer is more favorable than its competitors.

Summary

Seer competitors beat Seer on 8 of the 13 factors compared.

About Seer (Get Rating)

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Want More Great Investing Ideas?

Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.